Get Retatrutide Online in Wyoming | OmniRx Health
Medical Weight Loss Treatment in Wyoming
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Wyoming
Wyoming is the land of wide-open spaces—and sometimes, the nearest doctor is those wide-open spaces away. OmniRx Health bridges that gap for the Equality State, serving ranchers, energy workers, outdoor enthusiasts, and everyone in between. From the gateway towns of Yellowstone and Grand Teton to the plains of Eastern Wyoming, our telehealth platform brings expert medical care to the most sparsely populated state in the nation.
Our providers are licensed by the Wyoming Board of Medicine for comprehensive telehealth services across the Equality State.
Wyoming pharmacies in Cheyenne, Casper, and throughout the state provide prescription services with reliable statewide delivery.
Wyoming has embraced telehealth to address its unique geographic challenges, with laws supporting virtual care delivery.
Wyoming insurers cover telehealth services, recognizing virtual care's critical role in serving the state's spread-out population.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Wyoming?
- Yes, Wyoming fully supports telehealth as essential for serving its dispersed population. Licensed providers can offer comprehensive virtual care including prescriptions.
- Can Wyoming ranchers use telehealth?
- Telehealth is ideal for Wyoming's ranching and agricultural community. Get care without leaving your operation, even during the busiest seasons.
- How does telehealth work in Wyoming's remote areas?
- With internet access (including satellite), even Wyoming's most remote residents can connect with our providers. Telehealth eliminates the need for long drives across the plains.